Immunophenotyping without antibodies. New perspectives for lymphoma characterization

Area of Science:

• Hematology
• Oncology
• Proteomics

Background:

• Accurate classification of hematological malignancies is crucial for diagnosis, prognosis, and therapy.
• Lymphoma classification is challenging due to limited cell surface protein markers for immunophenotyping.

Purpose of the Study:

• To systematically and quantitatively analyze cell surface proteins for new lymphoma subtype markers.
• To employ an unbiased, discovery-driven approach to identify novel protein markers.

Main Methods:

• Cell surface capture (CSC) technology, a mass spectrometry-based method, was used to identify cell surface glycoproteins.
• Nine Hodgkin and non-Hodgkin B cell lines were analyzed.
• Selected proteins were verified using antibody-based methods like flow cytometry and immunohistochemistry.

Main Results:

• 747 predicted transmembrane proteins were identified, including 142 CD-annotated proteins.
• Quantitative CSC revealed differentially expressed glycoproteins between Hodgkin and non-Hodgkin B cell lines.
• CD2 was identified on Hodgkin lymphoma cell lines and verified in primary tissues, alongside expected markers like CD20 and CD30.

Conclusions:

• Cell surface capture technology is effective for identifying novel cell surface markers in lymphomas.
• The identified markers, including CD2, can improve lymphoma classification and potentially guide therapeutic strategies.
• Further investigation of CSC-identified glycoprotein candidates is ongoing using patient samples.